<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To investigate the association between human <z:mpath ids='MPATH_445'>papilloma</z:mpath> virus (HPV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Sixty-nine patients with pathologically confirmed primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> including 6 stage I, 24 stage II, 21 stage III, and 18 stage IV patients were enrolled in this study to investigate whether HPV 16 could be involved in colorectal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Nested-polymerase chain reaction (nested-PCR) was used to detect HPV16 DNA in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> tissues and further confirmed by in situ hybridization (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ISH</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, immunohistochemistry analysis was performed to examine the E6 oncoprotein in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>To verify whether E6 could inactivate the p53 transcriptional function, the levels of p21 and Mdm2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression were evaluated by real-time reverse transcription (RT)-PCR </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Of the 69 colorectal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, HPV16 DNA was detected in 11 (16%) by nested-PCR, and HPV16 DNA was present in 8 of the 11 (73%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> which was confirmed by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ISH</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The presence of HPV16 DNA in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> was not associated with patients' clinical parameters including age, gender, smoking status, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> site; however, HPV16 <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> was more common in stage I patients than in late-stages patients (II, III and IV) </plain></SENT>
<SENT sid="7" pm="."><plain>We next asked whether HPV16 <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> could be linked with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> development </plain></SENT>
<SENT sid="8" pm="."><plain>Immunohistochemical data indicated that 8 of the 11 HPV16 DNA-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had E6 oncoprotein expression </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, we also observed that the adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> tissues including endothelial cells, lymphocytes, fibroblasts, and gland cells in E6-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had E6 oncoprotein expression </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, 3 of the 4 (75%) E6-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> carrying p53 <z:mp ids='MP_0002169'>wild-type</z:mp> had negative immunostaining, but one <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> had less p53 immunostaining </plain></SENT>
<SENT sid="11" pm="."><plain>We further examined whether E6-positive and/or p53 mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> reduce p53 transcriptional activity </plain></SENT>
<SENT sid="12" pm="."><plain>Real-time RT-PCR analysis indicated that p21 and mdm2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels in E6/p53-<z:mp ids='MP_0002169'>wildtype</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were significantly lower than in their adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> tissues; as expected, E6-positive/p53-mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had lower p21 and mdm2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels compared with their adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> tissues </plain></SENT>
<SENT sid="13" pm="."><plain>These results clearly indicate that the E6 oncoprotein expressed in p53 <z:mp ids='MP_0002169'>wildtype</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> may reduce p21 and mdm2 expression via p53 inactivation </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: These results suggest that HPV16 <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> may be involved in a subset of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and we suggest that the transmission of HPV to the colon and rectum might occur through peripheral blood lymphocytes </plain></SENT>
</text></document>